SGHT
Sight Sciences, Inc.
SGHT lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
SGHT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
SGHT's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
SGHT PE Valuation
SGHT has no meaningful PE right now: it lost money over the past year.
SGHT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect SGHT's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
SGHT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.51 | +$0.39 |
| Q2 2026 | -$0.55 | +$0.41 |
| Q1 2026 | -$0.70 | +$0.28 |
| Q4 2025 | -$0.74 | +$0.29 |
| Q3 2025 | -$0.90 | +$0.12 |
| Q2 2025 | -$0.96 | +$0.11 |
| Q1 2025 | -$0.98 | +$0.14 |
| Q4 2024 | -$1.03 | +$0.11 |
SGHT is still losing money, but far less than before: $0.51 per share over the past year, against $2.81 at its worst in late 2021.
SGHT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.9M | +25% |
| Q2 2026 | $23.4M | +20% |
| Q1 2026 | $19.7M | +13% |
| Q4 2025 | $20.4M | +6.9% |
| Q3 2025 | $19.9M | -1.2% |
| Q2 2025 | $19.6M | -8.5% |
| Q1 2025 | $17.5M | -9.1% |
| Q4 2024 | $19.1M | +1.7% |
SGHT's revenue has grown year over year for four quarters in a row: $25M last quarter, up 25% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -25% | +15 points |
| Q2 2026 | -17% | +43 points |
| Q1 2026 | -63% | +16 points |
| Q4 2025 | -18% | +45 points |
| Q3 2025 | -40% | +16 points |
| Q2 2025 | -60% | -0.4 points |
| Q1 2025 | -79% | -2.7 points |
| Q4 2024 | -63% | -3.3 points |
SGHT's operating margin was −25% last quarter, up 15 points from the same quarter a year ago.
SGHT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.5M | +$6.4M |
| Q2 2026 | -$5.7M | +$2.1M |
| Q1 2026 | -$7.1M | +$4.5M |
| Q4 2025 | -$1.7M | +$1.9M |
| Q3 2025 | -$8.9M | -2958% |
| Q2 2025 | -$7.8M | +$1.8M |
| Q1 2025 | -$11.6M | -$1.7M |
| Q4 2024 | -$3.6M | +$3.2M |
SGHT has burned cash in almost every quarter: −$17M over the past year, against −$32M the year before.
SGHT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +621K shares |
| 1 year | +5.2% | +2.7M shares |
| 3 years | +13% | +6.5M shares |
| 5 years | +474% | +45.5M shares |
| Available history | +57% | +20.1M shares |
SGHT has 55M diluted shares, up 5.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
SGHT Net Leverage
SGHT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SGHT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 75.4 | Overbought |
| Stochastic | 91.0 | Overbought |
SGHT's weekly RSI is 75 (overbought) and its Stochastic is 91 (overbought).
SGHT PE vs Healthcare Sector
SGHT has no meaningful PE right now: it lost money over the past year.
SGHT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.25 | 19% above |
| 20 week MA | $7.85 | 40% above |
| 50 week MA | $6.42 | 71% above |
| 100 week MA | $5.07 | 117% above |
| 200 week MA | $5.73 | 92% above |
SGHT has climbed back above all five of its weekly moving averages, and it's now 92% above its 200-week average.
SGHT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $32.7 | $18.5 | -43% |
| 2022 | $18.5 | $12.1 | -35% |
| 2023 | $12.1 | $5.16 | -57% |
| 2024 | $5.16 | $3.57 | -31% |
| 2025 | $3.57 | $8.82 | +147% |
| 2026 YTD | $8.82 | $11.0 | +25% |
SGHT's yearly returns have swung widely, from +147% in 2025 to −57% in 2023. It's up 25% so far in 2026.